We studied the effectiveness ofaeroso l deli very of antibiotics to the sinuses via a nebulizer in 41 patients who had chronic. recurrent sinusitis that had persisted despite endoscopic sinus surgery and that had not responded to multiple courses of oral antibiotics. We compared preand post-treatment symptom scores in five categories: nasal obstruction. facia l pain. pressure, mucopurul ent rhinorrhea. and malaise. Following 3 to 6 weeks of treatment, 34 patients (82.9 %) experienced either an excellent or good response to treatment. Side effects were infrequent. mild. and transient. We conclude that nebulized antibiotics should be considered fo r all patients with chronic sinusitis who have undergonefun ctional endoscopic sinus surg ery and who have fa iled to respond to oral antibiotics or who do not tolerate them. From a private otolaryng ology practice, Sant a Barbara, Cal if. (Dr. Scheinberg), and the clini cal research group, Sinu sPharma, Inc., Carpinteri a, Calif. (Dr. Otsuji ). Repri nt req uests: Phili p A. Scheinberg, MD, 536 E. Arre llaga St., Suite 104, Santa Barbara, CA 93 103. Phone: (805) 884-1138; fax: (805) 884-0955. This community-bas ed resea rch project was co nducted at the oto laryngology office of Phil ip A. Schei nberg, MD , in Sa nta Barbara, Calif. Dr. Scheinberg is a memb er of the Scien tific Advisory Board of Sinu sPh arm a, Inc. 648
Introduction
Chronic sinusitis is one of the most common disea ses in the United States, affecting more than 30 million America ns.I Moreover, its incidence appears to be increasing. For example, between 1990 and 1992, patients with sinusitis reported that they had experienced approximately 73 million "re stricted-activity days," a significa nt increase over the 50 million such days that were repo rted between 1986 and 1988. 1 • 2 During the early 1990s, more than 13 million co urses of antibiotics for sinusitis were prescribed annually in the United States, representing a 125 % increase over the average numb er prescribed durin g the previous 10 yea rs.' The standard management regimen has been to adminis-ter a systemic antibiotic-usually an oral drug, but occasionally an intravenous agent-for 3 to 6 week s. Patients who do not respond to this regimen are often prescribed an additional course of therapy, which increases cos ts and the risk of adve rse reactions. ' A recent instituti onal study conducted at the Stanford (Calif.) University Medical Center demonstrated that the local delivery of nebuli zed antibiotics in patient s with chronic sinusitis safely led to an increa se in the duration of disease-free interva ls. ' We believe that such a benefit is equally important in the community setting. Therefore, we conducted a retrospective outpatient study to systematically determine the effect that nebuli zed antibiotics would have on five major signs and symptoms of chronic sinusitis''? in patients who had already undergone functional endosc opic sinu s surgery. Our goals were to make an informed assessment of the efficacy of this treatment modality and to record the inciden ce of adverse effects for the purpose of compiling safety profile information. In this article, we describe our findin gs.
Patients and methods
We reviewed the record s of 4 1 patients (mea n age: 53.9 yr) who had been treated with a nebulized antibiotic in the private-practice otolaryngo logy office of the lead author (P.A.S.) between Jul y 1999 and February 2002 . All patient s had clinical sig ns of acute sinus infec tion and at least a 2-year history of diag nosed chronic sinus disease. All had been previously treated with at least three cour ses of ora l antibiotics-some as many as 12 (mean: 7). All patients had undergone comp uted tom ography (CT) at least once. All patients had had at least one sinus operation, and allhad rece ived at least one postsurgical followup endosco pic sinus exa mination. The patient population was made up of24 women (mean age: 51.5 yr) and 17 men (mea n age : 57.4 yr).
Otolaryngologists adhere to severa l accepted criteria for determining the presence and severity of chronic sinusitis. For this study, we selected the five sign s and 
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Brief Summary (For full Prescribing Information, see package insert.) INDICATIONS AND USAGE: Allergic Rhinitis: CLARINEX Tablets 5 mg are indicated for the reli ef of the nasal and non-nasal symptoms of alle rg ic rhin itis (seasonal and perennial ) in pati ents 12 years of age and old er. Chronic Idiopathic Urticaria: CLARINEX Tablets are indicated for the symptomati c reli ef of pruritus, red uction in the number of hives, and size of hives, in pati ents with chronic idiopath ic urticaria 12 years of age and old er. CONTRAINDICATIONS: CLARINEX Tablets 5 mg are contraindicated in pati ents whoarehypersensiti veto this medication or to any of its ingredients, or to loratadin e. PRECAUTIONS: Carcinogenesis , Mutagenesis, Impairment of Fertility: The carcinogenic potential of desloratadine was assessed using loratadine studies. In an 18-month study in mice and a 2-year study in rats, loratadine was administered in the diet at doses up to 40 mg/kg/day in mi ce (estimated desloratadine and desloratadine metabolite exposures were approximately 3 times the AUC in humans at the recomm ended daily oral dose) and 25 mg/kg/day in rats (estimated desloratadine and desloratadine metabolite exposures were approximately 30 times the AUC in humans at the recommended dail y oral dose). Male mice given 40 mg/kg/day loratadine had a signifi cantly higherinciden ceof hepatocellulartumors (combined adenomas and carcino mas) than concurre nt controls. In rats, a sig ni ficantly higherincid ence of hepatocellular tumors (combined ade nomas and carcinomas) was observed in mal es given 10 mg/kg/day and in males and femal es given 25 mg/kg/day. Th e estimated desloratadine and desloratadine metabolite exposures of rats given 10 mg/kg of loratadine were approximately 7 times the AU Cin humans at the recomm ended daily oral dose. Th e clinical significance of these finding s during long-term use of desloratadine is notknown.
In genotoxicity studies with desloratadine, there was no evidence of genotoxic potential in a reverse mutation assay (Sa/mone//ai E. coli mammalian mi crosome bacteri al mutagenicity assay) or in two assays for chromosomal aberrations (human peripheral blood lymphocyte clastogenicity assay and mouse bone marrow micronu cleus assay).
Th ere was no effect on femal e fertility in rats at desloratadine doses up to 24 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 130times theAUC in humans at the recommend ed dail y oral dose). A male specific decreasein fertility, dem on strated by reduced female conception rates, decreased sperm numbers and motility, and histopathologic testicul ar changes, occurred at an oral desloratadine dose of 12 mg/kg in rats (estimated desloratadine exposures we re approximately 45 times theAUC in humans at the recommended dail y oral dose). Desloratadine had no effect on fertility in rats at an oral dose of 3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 8 times the AU Cin humans at the recomm ended dail y oral dose) .
Pregnancy Category C: Deslorat adine was notteratogenic in rats at doses up to 48 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approximately 210 times the AU C in humans at the recommended daily oral dose) or in rabbits at doses up to 60 mg/kg/day (estimated desloratadine exposures we re approxi mately 230times theAUC in humans at the recommend ed daily oral dose). Ina separate study, an increase in preimplantation loss and a decreased number of implantations and fetuses were noted in female rat s at 24 mg/kg (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the AUC in humans at the recommended dail y ora l dose). Reduced body weight and slow righting refl ex were reported in pups at doses of 9 mg/kg/day or greater (estimated desloratadine and desloratadine metabol ite exposures were approximately 50 times or greater than the AUC in humans at the recommended daily oral dose). Desloratadine had no effect on pup development at an oral dose of 3 mg/kg/day (estimated desloratadine and desloratadine metabolite exposures were approxi mately 7 times the AU C in humans at the recom mended dail y oral dose). There are, however, no adequate and well-controlled studies in pregnant women. Because animal rep roduction studies are notalways predictive of human response, desloratadine should be used during pregnancy only if clearly need ed .
Nursing Mothers: Desloratadine passe s into breast milk, therefore a decision should be madewhethe r to discontinue nursing orto discontinu e desloratadine, taking into account the importance of the drug to the mother.
Pediatric Use: The safety and effectiveness of CLARINEX Tabl ets in pediatric pati ents under 12years of age have notbeen established.
Geriatric Use: Clinical studies of desloratadine did not includ e sufficient numbers of subjects aged 65and overto determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences between the elderly and younge r patients. In general , dose selection for an elderl y pati ent should be cautious, reflectin g the greater frequency of decreased hepatic, renal , or cardiac function, and of concomitant disease or other drug therapy. (see CLINICAL PHARMACOLOGY -Special Populations).
Information for Patients: Patients should be instructed to use CLARINEX Tablets as directed. As thereare no food effects on bioavail ability, pati ents can be instructed that CLARINEX Tablets may be taken without regard to meal s. Pati ents should be advised not to increase the dose or dosing frequency as studies have not demonstrated increased effectiveness at higher doses and somnolence may occur. ADVERSE REACTIONS: Allergic Rhinitis: Inmultiple-dose pl acebo-controlled trial s, 2,834 patients recei ved CLARINEX Tablets at dose s of 2.5 mg to 20 mg dail y, of whom 1,655 pati ents rece ived the recommended daily dose of 5~g . In patients receiving 5 mg daily, the rate of adverse events was Similar between CLARINEX and placebo-treated pati ents. Th e percent of patients who withdrew pre maturely due to adverse events was 2.4% in the CLARINEX group and 2.6% in the placebo group. Th ere were no serious adverse events in thesetrials in pati ents recei vin g desloratadine. All adve rse events that were reported by greater than or equal to 2% of pati ents who recei ved the recommend ed dail y dose of CLARINEX Tablets (5.0 mg once-daily), and that we re more com mon with CLARINEXTabletthan placebo, are listed in Table 5 . There were no differences in adverse events for subgroups of pati ents as defined by gender, age, or race. Chronic Idiopathic Urticaria: In multiple-dose, placebo-controlled trials of chronic idiopathic urti cari a, 211 pati ents received CLARINEXTablets and 205 received placebo. Ad verse events thatwe re reported by greater than or equal to 2% of pati ents who recei ved CLARINEX Tablets and that were more common with CLARINEX than placebo were (rates for CLARINEX and placebo, respecti vely): head ache (14%, 13%), nausea (5%, 2%), fati gue (5%, 1%), dizziness (4%, 3%), pharyngitis (3%, 2%), dyspepsia (3%, 1%), and myalgia (3%, 1%).
The following spontaneous adverse events have been reported during the marketing of desloratadin e: tachycardi a, and rarely hypersensitivity reaction s (such as rash, pruritus, urticari a, edema, dyspnea, and anaphylaxis), and elevated liver enzymes including bilirubin . DRUG ABUSE AND DEPENDENCE: There is no information to indicate that abuse or dependency occurs with CLARINEXTablets. OVERDOSAGE: Information regarding acute overdosage is limited to experience from clinical trials conducted during the development of the CLARINEX product. In a dose ranging trial , at doses of 10 mg and 20 mg/day somnolence was reported .
Single dail y doses of 45 mg we re given to normal male and female volunteers for 10 days. All ECGs obt ained in this study were manually read in a blinded fashion by a cardiologist. InCLARINEX-treated subjects, therewas an increasein mean heartrateof 9.2bpm rel ati veto placebo. The aTinterval was corrected for heartrat e (aTe) by both the Bazettand Fridericia methods. Using the aTe(Bazett) there was a mean increase of 8.1 msec in CLARINEX-treated subjects re lative to placebo. Using aTe(Fridericia) therewas a mean increase of 0.4 msec in CLARINEX-treated subjects relati ve to placebo. No clinically rel evant adverse events we re reported.
In the event of overdose, consider standard measures to remove any unabsorbed drug . Symptom atic and supportive treatment is recommend ed. Desloratadine and 3-hydroxydesloratadine are noteliminated by hemodialysis.
Lethalit y occurred in rats at oral doses of 250 mg/kg or greater (estimated desloratadine and desloratadine metabolite exposures were approximately 120 times the AUCin humans at the recommend ed dail y ora l dose). The oral median lethal dose in mice was 353 mg/kg (estimated desloratadine exposures we re approximately 290 times the human dail y oral dose on a mg/m 2 basis). No deaths occurred at oral doses up to 250 mg/kg in monkeys (estimated desloratadine exposures were approximately 810 times the human dail y oral dose on a mg/m 2 basis). symptoms that we con sidered to be most important: nasal obstruction, facia l pain , pressure in the fore head and cheeks and around the eyes, mucopurulent rhinorrhea, and malaise. The severity of these signs and symptoms was rated on a scale of 0 (best possible condition) to 5 (worst possi ble condition). Scores were recorded both before and after nebulized antibiotic treatment. Eac h patie nt underwent a pre-and post -trea tment eva luatio n that includ ed clinical and endo scopic sinus exam inatio ns.
Each patient's respo nse to treatment was determined by analyzing scores across the five categories with a linearly adj usted methodology based on the Rhinosinu sitis Disability Index.t'" The treatment response was quantified by compiling the aggregate mean red uction-in-seve rity score. A reduc tion of 1.50 or more was considered excellent , 1.13 to 1.49 was good , 0.75 to 1.12 was fair, and less than 0.75 was poor.
Each patie nt used a nebulizer (Pari Respiratory Equipment; Mon terey , Calif.) to administer topically to the sinus mucosa one antibiotic: a compounded form ulatio n (SinusPharmacy ; Carpinteria , Calif. ) of eithercefuroxime at 285 mg three times daily, ciprofloxacin at 90 mg twice daily , levofloxacin at 70 mg twice daily, or tobr amycin at 95 mg twice daily. The choice of a particular antibiotic was based on the individual patient' s history and clinical characteris tics. The duration of treatment ranged from 3 to 6 weeks, depending on respon se.
Results
The nebulize d antibiotics were self-administered at home. Each dosing required 10 to 15 minutes to complete, and patients reported no difficult y in medicating them selves.
Treatment was found to be effec tive (i.e ., excellent or good) in 34 of the 41 patients (82 .9%). An excellent response was see n in 26 patients (63 .4%), a goo d respo nse in eigh t (19.5%), fair in six (14.6 %), and poor in only one (2.4 %). Every patient experienced reductio ns in severity scores in at leas t two of the five symptom catego ries, and no patient's scores increased in any category (tab le I).
The mea n aggregate score for all five symptom categories declined from 2.37 prior to treatment to 0.49 after treatment (table 2) . Mean red uctions in score s were seen in all five of the individual symptom categories:
Nasal obstruction. The degree of nasal obstruction of the sinus ostia was assessed by endo scopic examination. The pretreatment mean score was 2.66 and the posttreatment mean score was 0.66, which repre sented a substantial red uction in the degree of obstruc tion. Fo llowing treat ment, 20 of the 4 1 patients (48 .8%) had an obstruc tio n score of 0 (i.e ., a return to normal or nearnorma l) on endoscopic obse rvatio n.
Facial pain . Patients subjecti vely rated the presence of facia l pain or pain over the sinuses , as distinguished from Volume 81, Number 9 temporomandibular pain , den tal pain, or earache. The pretreatment mean score was 2.08 and the post-treatment mean score was 0.23 , which repre sented a significant reduction in the duration and degree of pain . Of the 4 1 patients, 32 (78 .0%) reported a score of 0 following treatment.
Pressure. Patie nts also subjectively rated the presence and degree of pressure in the forehead, cheeks, and periorbi tal area . The pretreatment mean score was 2.56 and the post-treatme nt mean score was 0.44 , agai n represe nting a sub stan tial reduction. A post-treatment score of 0 was repor ted by 24 patients (58.5%).
Mucopurulent rhinorrhea. Overall , the presence of thick purulent discharge was significant, as reflected by the pretreatment mean score of 3.02 . The post-treatment mea n score of0.68 indicated a substantial reduction in the quantity and thickness of the disc harge. Sixteen patient s (39.0%) had a post-treat ment score of 0 on clinical exa mination .
Malaise. The pretreatment mean score of 1.31 indicated that the presence and degree of malaise was minor. The post-treatment mean score of 0.41 represented some minor improvements in this area .
There were no significant differences in treatment responses based on sex , age, or the number of sinus operations. No patient experienced any serio us adverse effect, and none was forced to disco ntinue treatment. Only four mild side effects were reported: two cases of dry skin around the nose or lip, one case of throat/tongue irritation, and one case of cough. The dry skin resolved during treatment upon the application of an emo llient ointment. Th e ora l irritation and the co ugh reso lved upon the discont inuation of treatment at study 's end.
Discussion
Our study indica tes that the use of nebulized antibiotics for refracto ry, recurrent sinus infections is both effective and safe. The reduct ion in severity of the five signs and symptoms we meas ured reflects the effectiveness of this therapy, as does the high com bined rate of excellent and good responses (82.9%). In fact , nebulized therapy in this group of patients was superior to oral ther apy. All these patients had already undergone at least three courses of oral antibiotics, and all had a history of increasing intolerance to these agents.
Side effects were minor and tran sient. The safety profile indicates that nebulized antibiotic adm inistration is well tolerate d. No patie nt was forced to interrupt or discont inue treatment as a result of adverse effec ts.
We conclude that nebulized antibiot ics sho uld be co nsidered for all patien ts with chro nic sinusitis who have undergone functional endosco pic sinus surgery and who have failed to respond to oral antibio tics or who do not tolerate them . 
